Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery

NCT00041691 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00041691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00041691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
Not reported
Completion date
Not reported
Enrollment
30
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms